The compounded GLP-1 boom was a creature of shortage: while brand semaglutide and tirzepatide sat on FDA shortage lists, compounding pharmacies could produce copies at scale, and a massive telehealth economy grew around $150–$300 alternatives to $1,000+ brands. Then the shortages resolved, the FDA wound down mass copying, MFN pricing cut brand to $199 — and the market's entire reason for being was forced to evolve. Here's the honest 2026 state of play.
What Changed
- The legal basis narrowed. With shortages officially resolved, large-scale copying of the brand products lost its shortage-era justification. The surviving market operates in the narrower lanes that remain for compounding — and regulatory scrutiny of those lanes is ongoing and real.
- The field consolidated. The long tail of pop-up sellers thinned dramatically. What remains skews toward established telehealth programs with named pharmacy partners and actual clinical intake — a meaningfully better landscape for buyers, if a smaller one.
- The value proposition repriced. At $199 brand, "compounded because brand is unaffordable" mostly died. The surviving cases are specific: bundled all-in totals under brand's medication-only price, flat dose pricing, and formats brand doesn't make.
- Enforcement got visible. FDA warning letters to several telehealth/compounding operators over 2025–2026 marked the new normal: this is a watched market. (Programs we track that received letters carry disclosure banners on our pages — that's our standing policy.)
The 2026 Buyer's Checklist
Shopping the surviving market well means asking five questions every time:
- Which licensed pharmacy fills this? A named, state-licensed pharmacy is table stakes. Evasiveness here ends the conversation.
- Is there real prescriber screening? Health history, contraindication review, an actual clinician. "Instant approval" is a warning, not a feature.
- What exactly is in the preparation? Straight semaglutide/tirzepatide base, or additives? You're entitled to a plain answer.
- What's the recurring, at-your-dose price in writing? Teasers and dose tiers, per our standing guidance.
- Do they say the quiet part clearly? Honest programs state plainly that compounded medications are not FDA-approved. Programs that blur that line about their own product will blur other lines.
Programs Representative of the Surviving Market
Telos Rx (Semaglutide)
Flat-rate injectable semaglutide — the same price at starter dose and max dose.
Injectable compounded semaglutide — $49 first month on 12-mo plan · $99/mo (6-mo) · $129/mo (3-mo) · $199 month-to-month, flat at any dose
- No dose-based price increases
- Commitment length sets your rate
- Consult and shipping included
Compounded medications are not FDA-approved. They are prepared by licensed pharmacies but have not been evaluated by the FDA for safety, effectiveness, or quality.
Visit Telos Rx (Semaglutide) Paid linkGobyMeds
The lowest injectable price point we currently track.
Injectable compounded semaglutide $99/mo · tirzepatide $133/mo
- Among the lowest injectable prices tracked
- Direct pharmacy model
- Flat monthly pricing
Compounded medications are not FDA-approved. They are prepared by licensed pharmacies but have not been evaluated by the FDA for safety, effectiveness, or quality.
Visit GobyMeds Paid linkWellorithm
One of the lowest oral entry prices in the compounded market.
Compounded oral semaglutide tablets from $147/mo · oral tirzepatide from $249/mo
- Oral tablet format
- Among the lowest oral prices tracked
- Provider consult included
Compounded medications are not FDA-approved. They are prepared by licensed pharmacies but have not been evaluated by the FDA for safety, effectiveness, or quality.
Visit Wellorithm Paid linkBottom Line
Compounding didn't die with the shortages; it shrank to its defensible core. Know the three lanes where it still wins, run the five-question checklist without exceptions, and let the $199 brand era do what it does best — keep everyone honest.
Last updated August 2026. Compounded medications are not FDA-approved. Regulatory conditions continue to evolve; verify current status with any program.
See the Full Comparison Grid
Every provider and channel we track — price, format, and what's included — side by side.
Compare All ProvidersMore Comparisons
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All prescription medications discussed require evaluation by a licensed healthcare provider. Always consult your doctor before starting, stopping, or changing any medication. Individual results vary.
Affiliate Disclosure: CompareGLP-1 may earn a commission when you use links on this page, at no additional cost to you. Links marked "Paid link" are sponsored. Our comparisons are editorially independent — rankings and verdicts are never sold, and we never fabricate statistics, testimonials, or reviews.